Biocon Eyes Capital Utilisation and Profitability Growth

Capital Utilisation and Profitability have become the key focus areas for Biocon as the company moves beyond its aggressive expansion phase and shifts attention toward improving margins and operational efficiency.

After years of investing in manufacturing capacity, biosimilars, and research capabilities, the company now plans to generate stronger returns from its existing assets.

Shreehas Tambe , Managing director and CEO of Biocon stated that  Biocon will be focusing on capital utilisation and profitability after a phase of building capabilities as the company faces geopolitical and supply chain risks.

Post FY26 results, Tambe commented, “Over the past few years, we have invested materially to build global scale capability and capacity, particularly in biosimilars, insulins, peptides, and complex generics. The focus now shifts towards improving utilisation of the capacity we built, expanding margins and driving a steady improvement in terms of return on capital investment.”

In the last fiscal year, the company integrated its biosimilars business with its generics formulations and active pharmaceutical ingredients (APIs) business, creating a unified biopharmaceutical enterprise. The company now focuses on capital utilisation and profitability over expansion.

The company reported an operating profit of Rs 16,927 Cr in FY26, 13 percent above last year after adjusting for one-time generic Lenalidomide sales in FY25.

Also Read: India's Path to Billion-Dollar Drugs: Building a Strong Ecosystem

Consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) rose around 200 points on a like-to-like basis. However, Biocon’s consolidated net profit showed a critical decline of 74 percent, to Rs 368.8 Cr from Rs 1,429.4 Cr in FY25. For FY26, the board of directors recommended a final dividend of Rs 0.50 per share at the rate of 10 percent of the face value of the share.

The sharp drop in the net profit shows the cost of Biocon’s capacity-building phase, and now the company hopes to monetize through higher utilisation rates. Meanwhile, Tambe underscored that there is no material impact on the company’s financials due to the ongoing West Asia conflict.